Evaluation of the Renal Congestion, Perfusion and Function Before and After Diuretic Treatment in the ICU (ECHOFURO)

Renal congestion is a pathological state that can lead to acute kidney failure. Furosemide is known to lower renal congestion by its diuretic effect.

The aim of this trial is to study the reversibility of kidney congestion under diuretic therapy and assess through echodoppler parameters if it can improve renal perfusion and function in congestive ICU patients.

It could in fine lead to a better identification of patients that could benefit from diuretic therapy in the ICU.

Study Overview

• Status: Unknown
• Conditions: Renal Congestion
• Intervention / Treatment: Other: non applicable

• Study Type: Observational
• Enrollment (Anticipated): 120

Contacts and Locations

Study Locations

• France
  • Amiens, France, 80054
    • Not yet recruiting
    • CHU AMIENS-PICARDIE
    • Contact: Ousama ABOU ARAB; Phone Number: +33 6 22 66 24 84; Email: abouao@gmail.com
    • Principal Investigator: Ousama ABOU ARAB
  • Dijon, France, 21000
    • Not yet recruiting
    • CHU de Dijon
    • Contact: Pierre Grégoire GUINOT; Phone Number: +33 645871619; Email: guinotpierregregoire@gmail.com
    • Principal Investigator: Pierre Grégoire GUINOT
  • Strasbourg, France, 67091
    • Recruiting
    • Les Hopitaux Universitaires de Strasbourg
    • Sub-Investigator: Gharib AJOB
    • Contact: Thibaut WIPF; Phone Number: +33 3 69 55 12 64; Email: thibaut.wipf@chru-strasbourg.fr
    • Principal Investigator: Thibaut WIPF

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

• Sampling Method: Non-Probability Sample

Study Population

ICU patients under treatment by furosemide

Description

Inclusion Criteria:

• patient hospitalized in ICU
• under furosemide treatment

Exclusion Criteria:

• participation refusal
• uncontrolled shock (MAP<65mmHg)
• abdominal compartment syndrome
• diuretic administration in the 6 hours prior to inclusion
• renal replacement therapy or stage 4-5 chronic kidney disease
• atrial fibrillation
• no monitoring of CVP / invasive arterial pressure

Study Plan

How is the study designed?

Number of groups / cohorts

2

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
Patients with renal congestion	Other: non applicable; non applicable
Patients without renal congestion	Other: non applicable; non applicable

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Effects of diuretics	Evaluation of renal perfusion diuretic treatment by measuring the renal resistance index and the renal venous impedance index.	24 hours

Collaborators and Investigators

• Sponsor: University Hospital, Strasbourg, France

Study record dates

Study Major Dates

• Study Start (Actual): December 1, 2018
• Primary Completion (Anticipated): December 1, 2021
• Study Completion (Anticipated): December 1, 2021

Study Registration Dates

• First Submitted: July 30, 2018
• First Submitted That Met QC Criteria: October 12, 2018
• First Posted (Actual): October 15, 2018

Study Record Updates

• Last Update Posted (Actual): May 1, 2019
• Last Update Submitted That Met QC Criteria: April 29, 2019
• Last Verified: April 1, 2019

More Information

Terms related to this study

• Other Study ID Numbers: 7148

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: UNDECIDED

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No